BNH Investment

Oncosoft specializes in developing software solutions aimed at enhancing anti-cancer treatment. The company offers an Oncology Information Management Solution (OIMS) and employs artificial intelligence technologies to assist radiologists in cancer detection. Additionally, Oncosoft's applications utilize machine learning to automate various tasks in radiation therapy, including treatment site detection and organ contour generation. This automation allows radiation oncologists to focus more on patient care, ultimately improving the efficiency of radiation therapy and contributing to advancements in precision cancer therapy.

Bazbiomedic primarily focuses on offering an automatic repeat injection needle-less drug delivery device for the skin and beauty device.

LabInCube develops inCube materials capable of selective drug release, sustained release, and supporting complex raw materials.

AITRICS is focused on enhancing patient outcomes through a clinical decision support platform that leverages health data effectively. By utilizing machine learning technologies combined with evidence-based expert analysis, the platform provides real-time clinical insights aimed at transforming traditional reactive disease management into a more proactive, preventive, personalized, and participatory approach to healthcare. This innovative solution is designed to empower clinicians by enhancing treatment strategies and expanding their knowledge, ultimately facilitating better health management for patients. AITRICS comprises a dedicated team of professionals from diverse backgrounds, united by a shared vision to make data-driven health intelligence accessible to all.

Bertis Inc. is a proteomics-based molecular diagnostics company focused on developing and commercializing cancer-related biomarkers for early disease detection. Founded in 2014 and based in Seongnam, South Korea, the company offers Mastocheck, a screening method for diagnosing stage 1 breast cancer. Bertis is engaged in extensive research for biomarker development aimed at the early diagnosis of various carcinomas, as well as the creation of new therapeutic markers and co-markers. Utilizing advanced bio-big data analysis technologies, the company seeks to uncover biomarkers across multiple fields by integrating proteomics, genomics, and bioinformatics. Additionally, Bertis is developing an AI-based diagnostic platform to enhance the diagnosis of cancer and cardiac diseases, thereby enabling more effective early detection and treatment options for medical practitioners.

Novorex focuses on developing small-molecule drugs aimed at treating oncology and neurology diseases. The company employs advanced technologies, including artificial intelligence, to enhance drug development processes. By integrating biophysical analysis with in vitro and in vivo assays, Novorex aims to improve the efficacy of its new treatments, ultimately providing patients with innovative solutions for cancer and central nervous system disorders.

Tentech is a global aesthetic equipment company that focuses on providing advanced beauty laser treatments for personal care. The company specializes in dermatology lasers designed to lift skin, enhance elasticity, and reduce the appearance of wrinkles. By offering premium total lifting solutions, Tentech enables users to effectively care for their skin and achieve cosmetic improvements.

Medinno Inc. is a biotechnology company founded in 2016 and located in Suwon, South Korea. The company focuses on research and development of cell therapeutics derived from neural stem cells sourced from adult brain tissue. Medinno aims to address degenerative neurological diseases, including stroke and Alzheimer's disease, as well as conditions such as hypoxic-ischemic encephalopathy, neonatal refractory brain diseases, and severe intraventricular hemorrhages. By utilizing advanced technology, Medinno seeks to provide effective treatment options for these serious medical conditions, particularly in vulnerable populations like premature infants.

INTAKE foods is a company that specializes in food content development and branding, with a strong emphasis on innovation in the food industry. The company operates a food technology platform that aims to replace high-ecological-cost food resources with sustainable alternatives. It offers a diverse range of products made from Korean grains, vegetables, fruits, and nuts, including energy bars and coffee lines designed to provide essential vitamins and nutrients. This focus on healthy and sustainable food options enables consumers to enhance their well-being while supporting a culture of innovation in food consumption.

PinotBio, Inc., based in Suwon, South Korea, is a biotechnology company focused on researching and developing small molecule drugs in the fields of ophthalmology and oncology. The company is engaged in pre-clinical trials for NTX-101, a treatment designed for glaucoma, as well as other technologies targeting anticancer therapies through epigenetics. PinotBio aims to create innovative treatments that assist in managing refractory and relapsed cancers, enhancing the ability of healthcare providers to treat patients with life-threatening conditions. Founded in 2017, the company is dedicated to addressing unmet medical needs in these critical areas.

Onconic Therapeutics is dedicated to the research and development of innovative cancer treatments. The company focuses on creating next-generation anti-cancer therapies that target the mechanisms involved in cancer cell growth and DNA damage repair. By simultaneously suppressing key signal delivery agents and repair enzymes, Onconic aims to provide healthcare professionals with effective therapeutic options for treating various cancers.

Oncosoft specializes in developing software solutions aimed at enhancing anti-cancer treatment. The company offers an Oncology Information Management Solution (OIMS) and employs artificial intelligence technologies to assist radiologists in cancer detection. Additionally, Oncosoft's applications utilize machine learning to automate various tasks in radiation therapy, including treatment site detection and organ contour generation. This automation allows radiation oncologists to focus more on patient care, ultimately improving the efficiency of radiation therapy and contributing to advancements in precision cancer therapy.

New Base provides a systematic disaster training solution.

HEXAR Humancare develops and produces wearable robots.

IVIM Technology, Inc. specializes in the development and manufacture of advanced IntraVital Microscopy platforms and related medical devices. Based in Daejeon, South Korea, the company was founded in 2017 and focuses on live cell intravital imaging, which allows for the monitoring of drug efficacy and delivery in real-time within living organisms. Its technology enables the analysis of cellular interactions and the complex processes underlying human diseases, particularly in the context of new biopharmaceuticals, including immunological, cell, gene, and antibody therapies. IVIM Technology's services include whole tissue 3D imaging, providing comprehensive insights into drug performance at the cellular level.

ImmuneOncia Therapeutics Inc. is a biopharmaceutical company focused on developing anti-cancer drugs, particularly in the field of immuno-oncology. Established in 2016 as a joint venture between Yuhan Corporation and Sorrento Therapeutics, the company is headquartered in Yongin-Si, South Korea. ImmuneOncia's primary product is IMC-001, a monoclonal antibody currently undergoing Phase 1 clinical trials, aimed at treating various types of cancer. The company combines the drug development and antibody engineering expertise of its parent organizations to create safe and effective immunotherapies for oncology patients worldwide.

Colavo Salon is a rapidly growing customer management software company that caters to independent beauty professionals. Its platform streamlines back-office operations by automating tasks, which allows salon owners to focus on client engagement. Colavo's software offers a range of features, including online reservations, schedule management, sales tracking, and report generation, all designed to enhance operational efficiency. By implementing intelligent booking and customizable reminders, the platform has been shown to improve customer retention by up to 50%. This comprehensive approach enables beauty professionals to manage their entire business processes from a single, user-friendly platform.

Mitoimmune Therapeutics is a biotechnology company focused on drug research and development aimed at addressing mitochondrial dysfunction and related cellular disorders. The company is dedicated to creating treatments for diseases associated with mitochondrial dysfunction, including those that are necrotic and inflammatory in nature. Through its innovative approach, Mitoimmune Therapeutics seeks to enhance the quality of life for patients by providing effective therapeutic solutions for complex health issues linked to mitochondrial health.

Onegene Biotechnology is a biotechnology company focused on developing innovative protein-based therapeutics aimed at treating cancer, metabolic, and inflammatory diseases. The company utilizes advanced protein conjugation technology, which involves the connection of separate proteins to create recombinant proteins through post-translational fusion. This approach enables the production of complex proteins with large molecular weights, facilitating the development of multispecific drugs that target multiple pathways simultaneously. Onegene's unique ability to combine various molecular types, including Fab fragments, scFv, sdAb, peptides, cytokines, and enzymes, allows for unprecedented design flexibility and optimized physical properties. Consequently, this innovation expands the potential for effective treatments for complex and multifactorial diseases, offering prolonged benefits for patients.

Primoris Therapeutics is a medical research and development center.

Bertis Inc. is a proteomics-based molecular diagnostics company focused on developing and commercializing cancer-related biomarkers for early disease detection. Founded in 2014 and based in Seongnam, South Korea, the company offers Mastocheck, a screening method for diagnosing stage 1 breast cancer. Bertis is engaged in extensive research for biomarker development aimed at the early diagnosis of various carcinomas, as well as the creation of new therapeutic markers and co-markers. Utilizing advanced bio-big data analysis technologies, the company seeks to uncover biomarkers across multiple fields by integrating proteomics, genomics, and bioinformatics. Additionally, Bertis is developing an AI-based diagnostic platform to enhance the diagnosis of cancer and cardiac diseases, thereby enabling more effective early detection and treatment options for medical practitioners.

Dr. Noah Biotech is a pharmaceutical company focused on developing treatments for orphan diseases, particularly targeting rare neurological and muscular conditions. Utilizing artificial intelligence technology, the company aims to accelerate the drug development process, enabling patients to access effective therapies in a shorter timeframe. By concentrating on these specialized areas, Dr. Noah Biotech seeks to address unmet medical needs and improve outcomes for individuals affected by rare diseases.

CORELINESOFT develops medical software products.

AITRICS is focused on enhancing patient outcomes through a clinical decision support platform that leverages health data effectively. By utilizing machine learning technologies combined with evidence-based expert analysis, the platform provides real-time clinical insights aimed at transforming traditional reactive disease management into a more proactive, preventive, personalized, and participatory approach to healthcare. This innovative solution is designed to empower clinicians by enhancing treatment strategies and expanding their knowledge, ultimately facilitating better health management for patients. AITRICS comprises a dedicated team of professionals from diverse backgrounds, united by a shared vision to make data-driven health intelligence accessible to all.

Mitoimmune Therapeutics is a biotechnology company focused on drug research and development aimed at addressing mitochondrial dysfunction and related cellular disorders. The company is dedicated to creating treatments for diseases associated with mitochondrial dysfunction, including those that are necrotic and inflammatory in nature. Through its innovative approach, Mitoimmune Therapeutics seeks to enhance the quality of life for patients by providing effective therapeutic solutions for complex health issues linked to mitochondrial health.

JLK, Inc. is a South Korean company that specializes in AI-driven solutions for medical diagnosis and security. The firm develops an artificial intelligence medical analysis platform that provides on-site and real-time services connected to various hospital systems, addressing the diagnostic needs of healthcare professionals. JLK's offerings encompass medical management, treatment, and services related to brain diseases, such as ischemic stroke, hemorrhagic stroke, brain aneurysm, and Alzheimer’s disease, as well as conditions affecting the lungs, coronary artery disease, prostate cancer, and digital pathology. Headquartered in Cheongju, South Korea, JLK aims to enhance healthcare delivery through its advanced technological solutions.